Primary or secondary nonresponse to anti-TNF-alpha due to immunogenicity or treatment-related side effects and the growing presence of innovative biological therapies targeting different cytokines and immune processes raise a clear need for predictors of efficacy for anti-TNF-alpha treatment.
Fighting the Hype for Predictors of Efficacy in Inflammatory Bowel Disease
Lopetuso, L. R.;
2020-01-01
Abstract
Primary or secondary nonresponse to anti-TNF-alpha due to immunogenicity or treatment-related side effects and the growing presence of innovative biological therapies targeting different cytokines and immune processes raise a clear need for predictors of efficacy for anti-TNF-alpha treatment.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
